Hope for MSA: new drug aims to slow rare brain disease

NCT ID NCT07446894

Recruiting now Disease control Sponsor: Tokyo University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called MSA-01 to see if it can slow the worsening of multiple system atrophy (MSA), a rare and serious brain disease. About 140 people with MSA will get either MSA-01 or a placebo for 12 months. The main goal is to measure changes in movement and daily function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY (MSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY (MSA)

Contacts and locations

Locations

Chiba University Hospital
NOT_YET_RECRUITING

Chiba, Chiba, Japan
Hokkaido University Hospital
NOT_YET_RECRUITING

Sapporo, Hokkaido, Japan
Institute of Science Tokyo Hospital
NOT_YET_RECRUITING

Bunkyō-Ku, Tokyo, Japan
Kagoshima University Hospital
NOT_YET_RECRUITING

Kagoshima, Kagoshima-ken, Japan
Kyoto University Hospital
NOT_YET_RECRUITING

Kyoto, Kyoto, Japan
Kyushu University Hospital
NOT_YET_RECRUITING

Fukuoka, Fukuoka, Japan
NHO Higashisaitama National Hospital
NOT_YET_RECRUITING

Hasuda, Saitama, Japan
Nagoya University Hospital
NOT_YET_RECRUITING

Nagoya, Aichi-ken, Japan
National Center Hospital, National Center of Neurology and Psychiatry
NOT_YET_RECRUITING

Kodaira, Tokyo, Japan
Okayama University Hospital
NOT_YET_RECRUITING

Okayama, Okayama-ken, Japan
The University of Tokyo Hospital
RECRUITING

Bunkyō-Ku, Tokyo, Japan
Tottori University Hospital
NOT_YET_RECRUITING

Yonago, Tottori, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.